Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer.
作者信息
Khorana A A, Francis C W, Menzies K E, Wang J-G, Hyrien O, Hathcock J, Mackman N, Taubman M B
出版信息
J Thromb Haemost. 2008 Nov;6(11):1983-5. doi: 10.1111/j.1538-7836.2008.03156.x. Epub 2008 Sep 15.
Abstract
摘要
相似文献
1
Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer.
J Thromb Haemost. 2008 Nov;6(11):1983-5. doi: 10.1111/j.1538-7836.2008.03156.x. Epub 2008 Sep 15.
2
Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer.
Cancer Sci. 2021 Nov;112(11):4679-4691. doi: 10.1111/cas.15106. Epub 2021 Aug 30.
3
Venous thromboembolism in patients with pancreatic cancer: implications of circulating tissue factor.
Blood Coagul Fibrinolysis. 2011 Jun;22(4):295-300. doi: 10.1097/MBC.0b013e32834512f4.
4
Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism.
Thromb Res. 2010 Jun;125(6):511-2. doi: 10.1016/j.thromres.2009.09.019. Epub 2009 Oct 24.
5
High concentration of the plasma microparticles for venous thromboembolism associated with lung cancer.
Clin Respir J. 2020 May;14(5):481-487. doi: 10.1111/crj.13158. Epub 2020 Feb 19.
6
7
Venous Thromboembolism Risk Stratification: The Missing Link in Hospitalized Patients.
J Atheroscler Thromb. 2018 Nov 1;25(11):1087-1088. doi: 10.5551/jat.ED096. Epub 2018 May 7.
8
Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients.
Anticancer Res. 2010 Oct;30(10):4261-4.
9
Predictive value of tissue factor bearing microparticles in cancer associated thrombosis.
Thromb Res. 2010 Apr;125 Suppl 2:S89-91. doi: 10.1016/S0049-3848(10)70022-0.
10
Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study.
Thromb Res. 2017 Sep;157:9-15. doi: 10.1016/j.thromres.2017.06.021. Epub 2017 Jun 20.
引用本文的文献
1
Challenges with measuring tissue factor antigen and activity in human plasma.
Blood Vessel Thromb Hemost. 2024 Jul 31;1(4):100022. doi: 10.1016/j.bvth.2024.100022. eCollection 2024 Dec.
2
Tissue factor, factor VIII and IX in microvesicle-induced thrombosis and tumor growth of pancreatic cancer.
Thromb J. 2025 Apr 11;23(1):32. doi: 10.1186/s12959-025-00715-x.
3
The Role of Platelet Dysfunctions in the Pathogenesis of the Hemostatic-Coagulant System Imbalances.
Int J Mol Sci. 2025 Mar 19;26(6):2756. doi: 10.3390/ijms26062756.
4
Circulating, Extracellular Vesicle-Associated Tissue Factor in Cancer Patients with and without Venous Thromboembolism.
Biomolecules. 2025 Jan 8;15(1):83. doi: 10.3390/biom15010083.
5
PROGNOSTIC MARKERS FOR THROMBOTIC EVENTS IN PATIENTS WITH GASTRIC OR COLORECTAL ADENOCARCINOMAS.
Arq Bras Cir Dig. 2024 Nov 25;37:e1833. doi: 10.1590/0102-6720202400039e1833. eCollection 2024.
6
Tissue factor signalling modifies the expression and regulation of G1/S checkpoint regulators: Implications during injury and prolonged inflammation.
Mol Med Rep. 2025 Feb;31(2). doi: 10.3892/mmr.2024.13404. Epub 2024 Nov 29.
7
Microvesicle Tissue Factor Procoagulant Activity Is Elevated and Correlated With Disease Severity in Patients With Cirrhosis.
Liver Int. 2025 Apr;45(4):e16192. doi: 10.1111/liv.16192. Epub 2024 Nov 27.
8
Venous Thromboembolism in Patients with Glioblastoma: Molecular Mechanisms and Clinical Implications.
Thromb Haemost. 2025 May;125(5):421-434. doi: 10.1055/s-0044-1789592. Epub 2024 Aug 21.
9
Cancer progression and tumor hypercoagulability: a platelet perspective.
J Thromb Thrombolysis. 2024 Aug;57(6):959-972. doi: 10.1007/s11239-024-02993-0. Epub 2024 May 17.
10
The pathogenesis of cancer-associated thrombosis.
Int J Hematol. 2024 May;119(5):495-504. doi: 10.1007/s12185-024-03735-x. Epub 2024 Feb 29.
本文引用的文献
1
Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients.
Ann Oncol. 2007 Oct;18(10):1660-5. doi: 10.1093/annonc/mdm284. Epub 2007 Jul 28.
2
Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer.
Clin Cancer Res. 2007 May 15;13(10):2870-5. doi: 10.1158/1078-0432.CCR-06-2351.
3
Cancer statistics, 2007.
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66. doi: 10.3322/canjclin.57.1.43.
4
Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer.
Br J Cancer. 2007 Jan 29;96(2):290-5. doi: 10.1038/sj.bjc.6603552. Epub 2007 Jan 9.
5
Microparticle-associated tissue factor activity: a link between cancer and thrombosis?
J Thromb Haemost. 2007 Mar;5(3):520-7. doi: 10.1111/j.1538-7836.2007.02369.x. Epub 2006 Dec 13.
6
Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma.
Clin Cancer Res. 2005 Apr 1;11(7):2531-9. doi: 10.1158/1078-0432.CCR-04-0866.
7
Pancreatic cancer and thromboembolic disease.
Lancet Oncol. 2004 Nov;5(11):655-63. doi: 10.1016/S1470-2045(04)01606-7.
8
The presence and release of tissue factor from human platelets.
Platelets. 2002 Jun;13(4):247-53. doi: 10.1080/09537100220146398.
9
Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes.
Circulation. 2000 Feb 29;101(8):841-3. doi: 10.1161/01.cir.101.8.841.
10
In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant.
J Clin Invest. 1999 Jul;104(1):93-102. doi: 10.1172/JCI4985.
Zotero 插件